Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 151

1.

Targeting the leukemia microenvironment by CXCR4 inhibition overcomes resistance to kinase inhibitors and chemotherapy in AML.

Zeng Z, Shi YX, Samudio IJ, Wang RY, Ling X, Frolova O, Levis M, Rubin JB, Negrin RR, Estey EH, Konoplev S, Andreeff M, Konopleva M.

Blood. 2009 Jun 11;113(24):6215-24. doi: 10.1182/blood-2008-05-158311. Epub 2008 Oct 27.

PMID:
18955566
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

Inhibition of CXCR4 with the novel RCP168 peptide overcomes stroma-mediated chemoresistance in chronic and acute leukemias.

Zeng Z, Samudio IJ, Munsell M, An J, Huang Z, Estey E, Andreeff M, Konopleva M.

Mol Cancer Ther. 2006 Dec;5(12):3113-21.

PMID:
17172414
[PubMed - indexed for MEDLINE]
Free Article
3.

p53 activation of mesenchymal stromal cells partially abrogates microenvironment-mediated resistance to FLT3 inhibition in AML through HIF-1α-mediated down-regulation of CXCL12.

Kojima K, McQueen T, Chen Y, Jacamo R, Konopleva M, Shinojima N, Shpall E, Huang X, Andreeff M.

Blood. 2011 Oct 20;118(16):4431-9. doi: 10.1182/blood-2011-02-334136. Epub 2011 Aug 25.

PMID:
21868571
[PubMed - indexed for MEDLINE]
Free PMC Article
4.

Dynamic chemotherapy-induced upregulation of CXCR4 expression: a mechanism of therapeutic resistance in pediatric AML.

Sison EA, McIntyre E, Magoon D, Brown P.

Mol Cancer Res. 2013 Sep;11(9):1004-16. doi: 10.1158/1541-7786.MCR-13-0114. Epub 2013 Jun 10.

PMID:
23754844
[PubMed - indexed for MEDLINE]
Free PMC Article
5.

Impact of CXCR4 inhibition on FLT3-ITD-positive human AML blasts.

Jacobi A, Thieme S, Lehmann R, Ugarte F, Malech HL, Koch S, Thiede C, Müller K, Bornhäuser M, Ryser M, Brenner S.

Exp Hematol. 2010 Mar;38(3):180-90. doi: 10.1016/j.exphem.2009.12.003. Epub 2009 Dec 24.

PMID:
20035824
[PubMed - indexed for MEDLINE]
6.

Role of CXCR4 in the pathogenesis of acute myeloid leukemia.

Peled A, Tavor S.

Theranostics. 2013;3(1):34-9. doi: 10.7150/thno.5150. Epub 2013 Jan 13. Review.

PMID:
23382784
[PubMed - indexed for MEDLINE]
Free PMC Article
7.

Targeting of mTORC1/2 by the mTOR kinase inhibitor PP242 induces apoptosis in AML cells under conditions mimicking the bone marrow microenvironment.

Zeng Z, Shi YX, Tsao T, Qiu Y, Kornblau SM, Baggerly KA, Liu W, Jessen K, Liu Y, Kantarjian H, Rommel C, Fruman DA, Andreeff M, Konopleva M.

Blood. 2012 Sep 27;120(13):2679-89. Epub 2012 Jul 23.

PMID:
22826565
[PubMed - indexed for MEDLINE]
Free PMC Article
8.

Mutant FLT3: a direct target of sorafenib in acute myelogenous leukemia.

Zhang W, Konopleva M, Shi YX, McQueen T, Harris D, Ling X, Estrov Z, Quintás-Cardama A, Small D, Cortes J, Andreeff M.

J Natl Cancer Inst. 2008 Feb 6;100(3):184-98. doi: 10.1093/jnci/djm328. Epub 2008 Jan 29.

PMID:
18230792
[PubMed - indexed for MEDLINE]
Free Article
9.

Stromal cell-derived factor 1α mediates resistance to mTOR-directed therapy in pancreatic cancer.

Weekes CD, Song D, Arcaroli J, Wilson LA, Rubio-Viqueira B, Cusatis G, Garrett-Mayer E, Messersmith WA, Winn RA, Hidalgo M.

Neoplasia. 2012 Aug;14(8):690-701.

PMID:
22952422
[PubMed - indexed for MEDLINE]
Free PMC Article
10.

Using combination therapy to override stromal-mediated chemoresistance in mutant FLT3-positive AML: synergism between FLT3 inhibitors, dasatinib/multi-targeted inhibitors and JAK inhibitors.

Weisberg E, Liu Q, Nelson E, Kung AL, Christie AL, Bronson R, Sattler M, Sanda T, Zhao Z, Hur W, Mitsiades C, Smith R, Daley JF, Stone R, Galinsky I, Griffin JD, Gray N.

Leukemia. 2012 Oct;26(10):2233-44. doi: 10.1038/leu.2012.96. Epub 2012 Apr 3.

PMID:
22469781
[PubMed - indexed for MEDLINE]
Free PMC Article
11.

Selective Akt inhibitors synergize with tyrosine kinase inhibitors and effectively override stroma-associated cytoprotection of mutant FLT3-positive AML cells.

Weisberg E, Liu Q, Zhang X, Nelson E, Sattler M, Liu F, Nicolais M, Zhang J, Mitsiades C, Smith RW, Stone R, Galinsky I, Nonami A, Griffin JD, Gray N.

PLoS One. 2013;8(2):e56473. doi: 10.1371/journal.pone.0056473. Epub 2013 Feb 21.

PMID:
23437141
[PubMed - indexed for MEDLINE]
Free PMC Article
12.

Chemosensitization of acute myeloid leukemia (AML) following mobilization by the CXCR4 antagonist AMD3100.

Nervi B, Ramirez P, Rettig MP, Uy GL, Holt MS, Ritchey JK, Prior JL, Piwnica-Worms D, Bridger G, Ley TJ, DiPersio JF.

Blood. 2009 Jun 11;113(24):6206-14. doi: 10.1182/blood-2008-06-162123. Epub 2008 Dec 2.

PMID:
19050309
[PubMed - indexed for MEDLINE]
Free PMC Article
13.

CXCR4 chemokine receptor signaling induces apoptosis in acute myeloid leukemia cells via regulation of the Bcl-2 family members Bcl-XL, Noxa, and Bak.

Kremer KN, Peterson KL, Schneider PA, Meng XW, Dai H, Hess AD, Smith BD, Rodriguez-Ramirez C, Karp JE, Kaufmann SH, Hedin KE.

J Biol Chem. 2013 Aug 9;288(32):22899-914. doi: 10.1074/jbc.M113.449926. Epub 2013 Jun 24.

PMID:
23798675
[PubMed - indexed for MEDLINE]
Free PMC Article
14.

Internal tandem duplication mutations in FLT3 gene augment chemotaxis to Cxcl12 protein by blocking the down-regulation of the Rho-associated kinase via the Cxcl12/Cxcr4 signaling axis.

Onish C, Mori-Kimachi S, Hirade T, Abe M, Taketani T, Suzumiya J, Sugimoto T, Yamaguchi S, Kapur R, Fukuda S.

J Biol Chem. 2014 Nov 7;289(45):31053-65. doi: 10.1074/jbc.M114.568287. Epub 2014 Sep 18.

PMID:
25237195
[PubMed - indexed for MEDLINE]
15.

Silvestrol exhibits significant in vivo and in vitro antileukemic activities and inhibits FLT3 and miR-155 expressions in acute myeloid leukemia.

Alachkar H, Santhanam R, Harb JG, Lucas DM, Oaks JJ, Hickey CJ, Pan L, Kinghorn AD, Caligiuri MA, Perrotti D, Byrd JC, Garzon R, Grever MR, Marcucci G.

J Hematol Oncol. 2013 Mar 16;6:21. doi: 10.1186/1756-8722-6-21.

PMID:
23497456
[PubMed - indexed for MEDLINE]
Free PMC Article
16.

Stromal niche cells protect early leukemic FLT3-ITD+ progenitor cells against first-generation FLT3 tyrosine kinase inhibitors.

Parmar A, Marz S, Rushton S, Holzwarth C, Lind K, Kayser S, Döhner K, Peschel C, Oostendorp RA, Götze KS.

Cancer Res. 2011 Jul 1;71(13):4696-706. doi: 10.1158/0008-5472.CAN-10-4136. Epub 2011 May 5.

PMID:
21546568
[PubMed - indexed for MEDLINE]
Free Article
17.

Bone marrow stroma-mediated resistance to FLT3 inhibitors in FLT3-ITD AML is mediated by persistent activation of extracellular regulated kinase.

Yang X, Sexauer A, Levis M.

Br J Haematol. 2014 Jan;164(1):61-72. doi: 10.1111/bjh.12599. Epub 2013 Oct 10.

PMID:
24116827
[PubMed - indexed for MEDLINE]
Free PMC Article
18.

AMD3100 disrupts the cross-talk between chronic lymphocytic leukemia cells and a mesenchymal stromal or nurse-like cell-based microenvironment: pre-clinical evidence for its association with chronic lymphocytic leukemia treatments.

Stamatopoulos B, Meuleman N, De Bruyn C, Pieters K, Mineur P, Le Roy C, Saint-Georges S, Varin-Blank N, Cymbalista F, Bron D, Lagneaux L.

Haematologica. 2012 Apr;97(4):608-15. doi: 10.3324/haematol.2011.052779. Epub 2011 Nov 4.

PMID:
22058221
[PubMed - indexed for MEDLINE]
Free PMC Article
19.

Selective FLT3 inhibition of FLT3-ITD+ acute myeloid leukaemia resulting in secondary D835Y mutation: a model for emerging clinical resistance patterns.

Moore AS, Faisal A, Gonzalez de Castro D, Bavetsias V, Sun C, Atrash B, Valenti M, de Haven Brandon A, Avery S, Mair D, Mirabella F, Swansbury J, Pearson AD, Workman P, Blagg J, Raynaud FI, Eccles SA, Linardopoulos S.

Leukemia. 2012 Jul;26(7):1462-70. doi: 10.1038/leu.2012.52. Epub 2012 Feb 22.

PMID:
22354205
[PubMed - indexed for MEDLINE]
Free PMC Article
20.

Role of stromal microenvironment in nonpharmacological resistance of CML to imatinib through Lyn/CXCR4 interactions in lipid rafts.

Tabe Y, Jin L, Iwabuchi K, Wang RY, Ichikawa N, Miida T, Cortes J, Andreeff M, Konopleva M.

Leukemia. 2012 May;26(5):883-92. doi: 10.1038/leu.2011.291. Epub 2011 Oct 18.

PMID:
22005789
[PubMed - indexed for MEDLINE]
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk